| Previous Close | 1.4000 |
| Open | 1.6000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 1.6000 - 1.6000 |
| 52 Week Range | 1.2500 - 19.3725 |
| Volume | 155 |
| Avg. Volume | 4,437 |
| Market Cap | 4.199M |
| Beta (3Y Monthly) | 1.73 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.9150 |
| Earnings Date | Nov 12, 2018 - Nov 16, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.00 |
Point Roberts, Washington and Delta, British Columbia--(Newsfile Corp. - June 19, 2019) - Investorideas.com, a leading investor news resource covering biotechnology, pharmaceutical and cannabis stocks releases a sector snapshot reporting on how, as the now legalized cannabis industry has gained heavy traction federally with Health Canada approvals, this potentially helps open the doors for other OTC medications and wellness products.Companies featured include Innovus Pharmaceuticals, Inc. (OTCQB: INNV), Neptune Wellness Solutions Inc. (quote), (quote), ...
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that it has made significant progress on the regulatory and manufacturing steps needed to obtain market authorization from Health Canada to commercialize its FlutiCare® brand in Canada. The Company expects to secure the needed market authorization, manufacturing and supply of the product from an existing Canadian manufacturer during the second half of 2019 pending Health Canada approval. “We are pleased to announce progress relating to our plans to commercialize FlutiCare® in Canada as this will be our first international market for the product if approved by Health Canada,” said Innovus Pharma CEO, Dr. Bassam Damaj.
Point Roberts, Washington and Delta, British Columbia--(Newsfile Corp. - June 11, 2019) - Investorideas.com, a leading investor news resource covering biotechnology and pharmaceutical stocks releases a sector snapshot reporting on the ongoing growth of OTC pain medication due to consumer demand and a move away from traditional surgeries. More companies are taking a global approach and are seeking to gain approval not only in the US, but also European markets moving forward. Companies featured ...
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that it has received the CPNP notification number required to commercialize CarvaNum®, its product for muscle recovery, in all 28 member countries of the European Union. This represents the fifth Innovus Pharma product to receive CPNP notification in the European Union so far, the others being Zestra®, Zestra Glide®, Sensum+®, and Diabasens®.
Point Roberts, Washington and Delta, British Columbia--(Newsfile Corp. - June 4, 2019) - Investorideas.com, a leading investor news resource covering biotechnology and pharmaceutical stocks releases a sector snapshot reporting on the continued growth in OTC analgesics as consumers look for more affordable and effective options for pain. In a recent report from Digital Journal "The global OTC analgesics market is projected to register an above-average CAGR during 2017 to 2022. Global sales of ...
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that it has entered into a supply relationship with a third party to supply Innovus Pharma with omeprazole 20mg tablets and omeprazole 20mg 24 hour delayed release capsules indicated for the treatment of frequent heartburn under the approved abbreviated new drug application (“ANDA”) No. 207891 from the U.S. Food and Drug Administration (“FDA”). Innovus Pharma will launch the drug under its own trademark OmepraCare™ 20mg tablets and OmepraCare™ DR 20mg 24 hour delayed release capsules.
Innovus Pharmaceuticals, Inc. , an emerging over-the-counter consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases, today released the final voting results from the Annual Shareholders Meeting held ...
SAN DIEGO, CA / ACCESSWIRE / May 29, 2019 / Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the "Company") (INNV), an emerging over-the-counter ("OTC") consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men's and women's health and vitality and respiratory diseases, today announced that it will be presenting at the 9th annual LD Micro Invitational on Tuesday June 4th at 12:20 PM PST / 3:20 PM EST. Mr. Ryan Selhorn, Chief Financial Officer, along with the management team will be presenting and meeting with shareholders and investors.
Represents the Fourth Innovus Pharma Product Notification in the E.U. Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that it has received the CPNP notification number required to commercialize Diabasens® in all 28 member countries of the European Union. This represents the fourth Innovus Pharma product to receive CPNP notification in the European Union in the last few years, the others being for Zestra®, Zestra Glide® and Sensum+®.
Cash, inclusive of merchant processor holdback, of $2.9 million as of May 13, 2019
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases, announced today that its partner, Lavasta Pharma RFZ-LLC (“Lavasta”), a company based in Dubai, received approval from the Algerian Ministry of Health and Commerce to market and sell the Company’s Zestra® and Zestra Glide® products in that country. In addition, Innovus Pharma announced that it received a purchase order from Lavasta Pharma for these two products for approximately $186,000.
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that Taro Pharmaceuticals U.S.A., Inc. (“Taro”), will supply Innovus Pharma, through the Company’s wholesaler, Taro’s 5% Minoxidil Foam for men and women under its approved abbreviated new drug application (“ANDA”) No. 209074 from the U.S. Food and Drug Administration (“FDA”). Innovus Pharma will launch the drug under its own trademark Regoxidine™.
LOS ANGELES, CA / ACCESSWIRE / May 6, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Indivior PLC ("Indivior" ...
Innovus Pharmaceuticals, Inc., (“Innovus Pharma”) (INNV), today announced preliminary first quarter 2019 net revenue is estimated to be $5.4 million or an approximate 12.8% increase from the fourth quarter of 2018 and 18.0% increase from the first quarter of 2018. Innovus Pharma's first quarter 2019 anticipated revenue results are preliminary and based on the most current information available and are subject to completion of the condensed consolidated financial statements for the first quarter of 2019, which are to be filed with the SEC no later than May 15, 2019. “We continue to execute on our controlled growth and profitability plan with focusing our growth in profitable sales channels only,” stated Bassam Damaj, President and Chief Executive Officer of Innovus Pharma.
Akorn, Inc. (AKRX), a leading specialty generic pharmaceutical company, today announced that it received a new Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC). Douglas Boothe, Akorn’s President and Chief Executive Officer, stated, “We are excited to add to our Fluticasone franchise and look forward to expanding into the over-the-counter (OTC) market. Fluticasone propionate nasal spray USP, 50 mcg per spray is indicated for the temporary relief of hay fever and other upper respiratory allergies in adult and pediatric patients 4 years of age and older.
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has approved abbreviated new drug application (“ANDA”) No. 208024 for Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC) owned by Akorn, Inc. (“Akorn”) (AKRX). Innovus has a manufacturing and supply agreement with Akorn for the supply of FlutiCare®.
Innovus Pharma (INNV) announced 4Q18 and full year results on April 1, 2019. To us, results signaled a change in corporate priorities, with the Company focused on informed, profitable growth, rather than aiming for the fastest top-line growth possible. As we mention in our initiation report (10/02/18), in 2018 the Company moved out of an advanced start-up phase to full commercial operations.
Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women’s health and respiratory diseases, today announced that its marketed product UriVarx® has received approval for an expanded claim to include “helps improve the symptoms of urinary incontinence.” Innovus Pharma currently sells this product in Canada exclusively through its distributor, Acerus Pharmaceuticals Corporation (“Acerus”). “We are very happy to receive Health Canada’s expanded claim for improving the symptoms of urinary incontinence, which we believe is a significant market in that country,” said Dr. Bassam Damaj, the President and Chief Executive Officer of Innovus Pharma.
ORLANDO, FL, April 02, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CEOLIVE, a provider of in-depth video interviews with public company CEO’s, announced the release of the latest episode of CEORoadshow featuring an interview with the CEO of Innovus Pharmaceuticals, Inc. (OTCQB: INNV, INNVD), Dr. Bassam Damaj. “Innovus Pharma first appeared on our show in 2013 but has become a completely different company since that time boasting three straight years of revenue growth, a highly successful and fast-growing product line of men’s and women’s health supplements and a unique direct-to-consumer sales and marketing platform,” stated Mike Elliott, Host of CEORoadshow. In the interview, Dr. Damaj discusses the company’s impressive growth in terms of revenues and product portfolio and explains how Innovus Pharma was able to grow its revenues consistently for the past three years.
Revenue growth of 2.7x compared to Fiscal 2017 Revenues
Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB:INNVD) today announced preliminary annual 2018 net revenue is estimated to be $24.0 million or approximately 2.7x the annual 2017 net revenue of $8.8 million. Innovus Pharma’s annual 2018 anticipated net revenue results are preliminary and based on the most current information available and are subject to completion of the audited consolidated financial statements for the year ended December 31, 2018, which are to be filed with the Securities and Exchange Commission (“SEC”) as part of the Company’s Annual Report on Form 10-K (“Annual Report”) no later than April 1, 2019. Actual results may differ from the preliminary results reported herein.
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that it launched in Canada its product Diabasens® as a Natural Health Product (“NHP”), for the indication to relieve cutaneous pain associated with diabetic neuropathy. The product is available as an over-the-counter (“OTC”) or behind the counter product and does not require a prescription.
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that received approval from Health Canada to market its product RecalMax™ as a Natural Health Product (“NHP”), for the indications to temporarily relieve symptoms of mental fatigue and sensation of weakness and support cognitive functions including mental focus and stamina. The product will be available as an over-the-counter (“OTC”) or behind the counter product and will not require a prescription.
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, today announced that it received approval from Health Canada to market its product Diabasens® as a Natural Health Product (“NHP”), for the indication to relieve cutaneous pain associated with diabetic neuropathy. The product will be available as an over-the-counter (“OTC”) or behind the counter product and will not require a prescription.